icon-facebook icon-instagram icon-pinterest icon-soundcloud icon-twitter icon-youtube

Group proceeding brought on behalf of those persons who purchased shares in the defendant (Mayne Pharma) in the period 24 November 2014 to 15 December 2016.

The claim alleges that Mayne breached its continuous disclosure obligations and engaged in misleading and deceptive conduct in relation to information it failed to provide to investors about an alleged price-fixing and market-share arrangement in the United States with executives of Heritage Pharmaceuticals, Inc, an American competitor to Mayne Pharma, which was the subject of a subpoena from the US Department of Justice, and later a subpoena and civil proceedings commenced by the Attorney General for the State of Connecticut.

The claim alleges that Mayne’s share price was inflated by its disclosure failures, and that shareholders suffered loss and damage as a result.

Defence filed by Mayne Pharma on 17 December 2021 in the Mayne Pharma Group Proceeding (Class Action)

Publisher
Supreme Court of Victoria
Date of publication

Statement of Claim filed on 8 October 2021 in the Mayne Pharma Group Proceeding (Class Action)

Publisher
Supreme Court of Victoria
Date of publication

Funding Information Summary Statement filed on 21 August 2020 in the Mayne Pharma Group Proceeding (Class Action)

Publisher
Supreme Court of Victoria
Date of publication

Summary Statement filed on 21 August 2020 in the Mayne Pharma Group Proceeding (Class Action)

Publisher
Supreme Court of Victoria
Date of publication